Phase 3 Recruiting Academic/Other
This phase III trial compares stereotactic body radiation therapy (SBRT), (five treatments over two weeks using a higher dose per treatment) to usual radiation therapy (20 to 45 treatments over 4 to 9 weeks) for the treatment of high-risk …
Sponsor: NRG Oncology
NCT ID: NCT05946213
Sites in Washington: - PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
- Fred Hutchinson Cancer Center — Seattle, Washington
- FHCC at Northwest Hospital — Seattle, Washington
- University of Washington Medical Center - Montlake — Seattle, Washington
Phase 3 Recruiting Network
This study is being done to answer the following question: can the chance of prostate cancer growing or spreading be lowered by adding a drug to the usual combination of drugs? This study would like to find out if this approach is better o…
Sponsor: Canadian Cancer Trials Group
NCT ID: NCT06592924
Sites in Washington: - Providence Regional Cancer System-Aberdeen — Aberdeen, Washington
- FHCC Overlake — Bellevue, Washington
- PeaceHealth Saint Joseph Medical Center — Bellingham, Washington
- Providence Regional Cancer System-Centralia — Centralia, Washington
- Swedish Cancer Institute-Edmonds — Edmonds, Washington
Phase 3 Recruiting Network
This phase III trial studies how well standard systemic therapy with or without definitive treatment (prostate removal surgery or radiation therapy) works in treating participants with prostate cancer that has spread to other places in the…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03678025
Sites in Washington: - FHCC Overlake — Bellevue, Washington
- Seattle Cancer Care Alliance at EvergreenHealth — Kirkland, Washington
- FHCC South Lake Union — Seattle, Washington
- FHCC at Northwest Hospital — Seattle, Washington
- University of Washington Medical Center - Montlake — Seattle, Washington
Phase 3 Recruiting Academic/Other
This randomized phase III trial examines whether lengthening the dosage interval in an adaptive manner for the prostate cancer drug lutetium 177 Lu PSMA RLT improves quality of life without decreasing lifespan when compared to the standard…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07200830
Sites in Washington: - Swedish Cancer Institute-Edmonds — Edmonds, Washington
- Swedish Medical Center-First Hill — Seattle, Washington
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received …
Sponsor: Pfizer
NCT ID: NCT07028853
Sites in Washington: - Northwest Medical Specialties, PLLC — Bonney Lake, Washington
- Northwest Medical Specialties, PLLC — Federal Way, Washington
- Northwest Medical Specialties, PLLC — Gig Harbor, Washington
- Northwest Medical Specialties, PLLC — Puyallup, Washington
- Northwest Medical Specialties, PLLC — Tacoma, Washington
Phase 3 Recruiting Industry
The purpose of this study is to find out whether treatment with pasritamig and docetaxel prolongs radiographic progression free survival (rPFS) (the length of time from start of treatment until disease worsens as determined by scans or dea…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07225946
Sites in Washington: - Fred Hutch Cancer Center Sloan Clinic 2 — Seattle, Washington
- Fred Hutchinson Cancer Research Center — Seattle, Washington
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 wit…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT07164443
Sites in Washington: - VA Puget Sound Healthcare System — Seattle, Washington
- Fred Hutchinson Cancer Research Center — Seattle, Washington
- University of Washington — Seattle, Washington
Phase 3 Recruiting Industry
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this …
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06925737
Sites in Washington: - VA Puget Sound Health Care System ( Site 0054) — Seattle, Washington
- Fred Hutchinson Cancer Center ( Site 0060) — Seattle, Washington
Phase 3 Recruiting Industry
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) i…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06136624
Sites in Washington: - Fred Hutchinson Cancer Center ( Site 0013) — Seattle, Washington
Phase 3 Recruiting Industry
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's choice (docetaxel, cabazitaxel, or abiraterone).
Sponsor: Amgen
NCT ID: NCT07213674
Sites in Washington: - Northwest Medical Specialties, PLLC — Tacoma, Washington
Phase 3 Recruiting Industry
The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in particip…
Sponsor: AstraZeneca
NCT ID: NCT06952803
Sites in Washington: - Research Site — Seattle, Washington
Phase 3 Recruiting Industry
This study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
Sponsor: Pfizer
NCT ID: NCT06629779
Sites in Washington: - Northwest Medical Specialties, PLLC — Bonney Lake, Washington
- Northwest Medical Specialties, PLLC — Federal Way, Washington
- Northwest Medical Specialties, PLLC — Gig Harbor, Washington
- Northwest Medical Specialties, PLLC — Puyallup, Washington
- Harborview Medical Center — Seattle, Washington
Phase 2 Recruiting Academic/Other
This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested …
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT06632977
Sites in Washington: - Swedish Cancer Institute-Edmonds — Edmonds, Washington
- Swedish Medical Center-First Hill — Seattle, Washington
Phase 2 Recruiting Industry
This is an open-label, multi center study to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of PF-07248144 and early signs of clinical efficacy of PF-07248144 as a single agent and in combination with other…
Sponsor: Pfizer
NCT ID: NCT04606446
Sites in Washington: - Swedish Cancer Institute — Seattle, Washington
- Swedish Medical Center — Seattle, Washington
Phase 2 Recruiting Industry
This is an open-label, randomized, Phase 2b study of ZEN003694 in combination with enzalutamide vs. enzalutamide monotherapy in patients with mCRPC who have progressed on prior abiraterone by PCWG3 criteria. Disease must have progressed on…
Sponsor: Zenith Epigenetics
NCT ID: NCT04986423
Sites in Washington: - Seattle Cancer Care Alliance — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This is a first-in-human, Phase 1/2, open-label, dose escalation, dose expansion and combination study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of Peluntamig (PT217) as a m…
Sponsor: Phanes Therapeutics
NCT ID: NCT05652686
Sites in Washington: - Fred Hutch Cancer Center — Seattle, Washington
Phase 2 Recruiting Industry
The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have successfully estimated g values that accurat…
Sponsor: Sun Pharmaceutical Industries Limited
NCT ID: NCT05422911
Sites in Washington: - VA Puget Sound Health Care System — Seattle, Washington
Phase 2 Recruiting Federal
The purpose of this study is to learn about how an investigational drug intervention completed before doing prostate surgery (specifically, radical prostatectomy with lymph node dissection) may help in treatment of high risk localized pros…
Sponsor: VA Office of Research and Development
NCT ID: NCT05593497
Sites in Washington: - VA Puget Sound Health Care System Seattle Division, Seattle, WA — Seattle, Washington
Phase 2 Recruiting Academic/Other
The goal of this clinical trial is to measure the toxicity and effectiveness of the following treatments for cFIR/cgUIR prostate cancer patients. Stereotactic body radiotherapy (SBRT) alone or Stereotactic body radiotherapy (SBRT) combined…
Sponsor: Yale University
NCT ID: NCT06111781
Sites in Washington: - University of Washington — Seattle, Washington
Phase 2 Recruiting Academic/Other
This phase II trial tests how well 177Lu-PSMA-617 works in treating patients with prostate cancer that has spread from where it first started (primary site) to other places in the body (metastatic) and that remains despite treatment (resis…
Sponsor: University of Washington
NCT ID: NCT06526299
Sites in Washington: - Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Phase 2 Recruiting Academic/Other
This phase II trial tests how well vorinostat works in treating patients with prostate-specific membrane antigen (PSMA)-low castration-resistant prostate cancer that has spread from where it first started (primary site) to other places in …
Sponsor: Fred Hutchinson Cancer Center
NCT ID: NCT06145633
Sites in Washington: - Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Phase 1 Recruiting Industry
The objective of this study is to evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BL-M14D1 in Subjects with locally Advanced or Metastatic Small Cell Lung Cancer and Other Neuroendocrine Neoplasms
Sponsor: SystImmune Inc.
NCT ID: NCT07080242
Sites in Washington: - University of Washington/Fred Hutchinson Cancer Center — Seattle, Washington
Phase 1 Recruiting Industry
Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with adv…
Sponsor: Astellas Pharma Global Development, Inc.
NCT ID: NCT04729114
Sites in Washington: - Northwest Medical Specialties — Tacoma, Washington
Phase 1 Recruiting Industry
The purpose of this study is to establish the safety and preliminary antitumor activity of ORIC-944 as a single agent and in combinations with ARPIs in patients with metastatic prostate cancer.
Sponsor: ORIC Pharmaceuticals
NCT ID: NCT05413421
Sites in Washington: - University of Washington, Fred Hutchinson Cancer Center — Seattle, Washington
Phase 1 Recruiting Industry
The purpose of Parts 1, 2A, and 2B of the study is to determine the recommended regimen for Phase 2 (RP2Rs) of combination of JNJ-87189401 with JNJ-78278343 and the purpose of Part 2C of this study is to determine how safe the RP2R(s) of t…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT06095089
Sites in Washington: - Swedish Medical Center — Seattle, Washington